Shield Therapeutics plc
("Shield" or the "Company")
Grant of Share Awards
London, UK, 11 March 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that it has granted awards in the form of options over ordinary shares in the capital of the Company ("Award Shares") to the following directors under its Long Term Incentive Plan ("LTIP").
Carl Sterritt: 371,069
Richard Jones: 270,440
In total awards have been granted over 1,773,581 shares under the LTIP. The exercise price per Award Share is 1.5 pence and awards are exercisable between February 2019 and February 2026, subject to applicable performance conditions having been satisfied. The grant of awards is part of the Company's long-term incentive arrangements designed to directly align the interest of the shareholders and executives.
The Company's LTIP was adopted by the Board on 12th February 2016. The LTIP provides for awards of ordinary shares to be made to eligible employees. The arrangements are described more fully in the Admission Document, a copy of which is available on the Company's website (www.shieldtherapeutics.com).
-Ends-
For further information please contact:
Shield Therapeutics plc |
+44 (0)191 511 8507 |
Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer |
|
|
|
Nominated Adviser and Sole Bookrunner Liberum Capital Limited Christopher Britton Steve Pearce Jamil Miah |
+44 (0)20 3100 2222 |
|
|
Financial PR Advisor Consilium Strategic Communications |
+44 (0)203 709 5700 [email protected] |
Mary-Jane Elliott Matthew Neal Lindsey Neville Hendrik Thys |
|
